Spero Therapeutics (NASDAQ:SPRO) PT Lowered to $5.00

Spero Therapeutics (NASDAQ:SPROGet Rating) had its target price lowered by investment analysts at Cantor Fitzgerald from $27.00 to $5.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Cantor Fitzgerald’s target price suggests a potential upside of 247.22% from the company’s current price.

A number of other equities research analysts have also issued reports on SPRO. Cowen lowered Spero Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 4th. HC Wainwright cut their price objective on Spero Therapeutics from $43.00 to $37.00 and set a “buy” rating for the company in a research report on Monday, April 18th. Finally, Zacks Investment Research lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 5th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Spero Therapeutics has an average rating of “Hold” and a consensus price target of $30.44.

Shares of SPRO stock opened at $1.44 on Tuesday. Spero Therapeutics has a 52-week low of $1.43 and a 52-week high of $19.87. The firm has a market capitalization of $47.17 million, a PE ratio of -0.44 and a beta of 1.87. The stock has a fifty day simple moving average of $5.77 and a two-hundred day simple moving average of $10.46.

Spero Therapeutics (NASDAQ:SPROGet Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14). Spero Therapeutics had a negative return on equity of 87.72% and a negative net margin of 491.65%. During the same period in the previous year, the business posted ($0.66) earnings per share. Equities analysts anticipate that Spero Therapeutics will post -2.97 earnings per share for the current fiscal year.

In related news, major shareholder Aquilo Capital Management, Llc purchased 39,727 shares of the company’s stock in a transaction that occurred on Tuesday, April 26th. The stock was bought at an average price of $5.24 per share, for a total transaction of $208,169.48. Following the completion of the transaction, the insider now owns 5,321,231 shares in the company, valued at approximately $27,883,250.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 13.45% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SPRO. Marshall Wace LLP purchased a new position in Spero Therapeutics in the first quarter worth about $39,000. Patriot Financial Group Insurance Agency LLC purchased a new position in Spero Therapeutics in the fourth quarter worth about $66,000. BNP Paribas Arbitrage SA grew its position in Spero Therapeutics by 358.6% in the third quarter. BNP Paribas Arbitrage SA now owns 4,343 shares of the company’s stock worth $80,000 after acquiring an additional 3,396 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Spero Therapeutics in the first quarter worth about $95,000. Finally, XTX Topco Ltd bought a new stake in Spero Therapeutics in the first quarter worth about $115,000. Institutional investors own 69.36% of the company’s stock.

Spero Therapeutics Company Profile (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Further Reading

The Fly logo

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.